Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 4.8% - Should You Buy?

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) rose 4.8% during trading on Monday . The stock traded as high as $11.95 and last traded at $11.79. Approximately 1,310,184 shares traded hands during trading, a decline of 11% from the average daily volume of 1,475,259 shares. The stock had previously closed at $11.25.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. HC Wainwright reaffirmed a "buy" rating and set a $77.00 target price on shares of Capricor Therapeutics in a report on Monday, March 17th. Cantor Fitzgerald restated an "overweight" rating and issued a $30.00 target price on shares of Capricor Therapeutics in a report on Thursday, March 20th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $34.50.

Capricor Therapeutics Trading Up 0.9 %

The firm has a 50 day moving average of $12.18 and a two-hundred day moving average of $14.94. The company has a market cap of $606.13 million, a PE ratio of -12.52 and a beta of 4.65.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.15. The business had revenue of $11.13 million for the quarter, compared to analysts' expectations of $9.87 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. On average, research analysts forecast that Capricor Therapeutics Inc will post -1.21 EPS for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in Capricor Therapeutics by 44.4% in the 4th quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company's stock worth $31,420,000 after buying an additional 700,243 shares during the period. Farallon Capital Management LLC acquired a new stake in Capricor Therapeutics during the 4th quarter worth about $31,056,000. Geode Capital Management LLC raised its stake in shares of Capricor Therapeutics by 37.8% in the fourth quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company's stock worth $12,139,000 after purchasing an additional 241,279 shares during the last quarter. Altium Capital Management LLC boosted its position in Capricor Therapeutics by 150.5% in the fourth quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company's stock valued at $9,853,000 after buying an additional 429,000 shares during the last quarter. Finally, Woodline Partners LP purchased a new position in Capricor Therapeutics during the 4th quarter worth approximately $8,693,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.